Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
There are no standard chemotherapy regimens for metastatic esophageal cancer. Cisplatin plus
5-fluorouracil is widely used as first-line treatment with a response rate ranged from 30% to
40%. Combination of paclitaxel and cisplatin has been investigated in small size clinical
trial, producing promising outcome.Liposome capsuled paclitaxel has been proved to be as
effective as paclitaxel.The usefulness of the the regimen of paclitaxel liposome with
cisplatin is evaluated by median survival time, progression free survival,and response rate.